Cardiff Oncology, Inc. quarterly report, Q1 FY2018

Trovagene, Inc. (10-Q) — Quarter ended March 31, 2018

Entity note: The filing identifies the registrant as Trovagene, Inc., not Cardiff Oncology, Inc. This summary reflects the filing provided.

Business context and reporting period

Unaudited results cover the three months ended March 31, 2018, compared with the same period in 2017. Trovagene was a clinical-stage oncology therapeutics company developing PCM-075, an oral PLK1 inhibitor, while also generating limited revenue from royalties, diagnostic services, and clinical research.

Financial results and liquidity

Revenue increased by $5,098. Royalties were $49,055, diagnostic services $40,002, and clinical research $11,079. No profit margin was reported; the company remained loss-making. Total liabilities were $5.73 million, including $1.17 million of current equipment-line debt at quarter-end. On April 6, 2018, the company paid approximately $1.1 million to repay that loan in full.

Changes versus prior comparable period

Net loss narrowed by approximately $5.21 million, primarily as operating expenses fell by $5.47 million. Research and development expense declined to $1.88 million from $4.28 million, mainly because Q1 2017 included a $2.0 million PCM-075 license fee and staffing costs were lower. Selling, general and administrative expense decreased to $2.50 million from $3.60 million, primarily following workforce reductions. Q1 2017 also included $1.72 million in restructuring charges. Cash used in operations fell by $5.90 million. Weighted-average shares rose to 55.36 million from 30.96 million, reflecting warrant exercises and vested restricted stock units.

Outlook, risks, and unusual items

• Going concern and financing: Management said existing resources were expected to fund planned operations only through July 2018. The filing states substantial doubt exists about the company’s ability to continue as a going concern; significant additional capital is needed. Potential funding routes include equity offerings, partnerships, new revenue initiatives, and cost reductions. Failure to obtain funding could force delays, scaling back, or discontinuation of programs, and equity financing could dilute shareholders.
• Clinical development: The company was enrolling a Phase 1b/2 PCM-075 combination trial in acute myeloid leukemia and planned to begin a Phase 2 combination trial in metastatic castration-resistant prostate cancer later in 2018. Development, safety, efficacy, regulatory, and financing outcomes remain uncertain; the filing provides no financial guidance.
• NASDAQ listing: The company received an additional compliance period through September 4, 2018 to meet the $1.00 minimum bid-price requirement for at least ten consecutive business days.
• Accounting change: Adoption of ASC 606 increased the cumulative opening equity balance by $109,922. The standard reduced Q1 2018 revenue by a net $59,263 versus prior guidance and increased net loss by the same amount; it had no effect on operating cash flow.
• Other items: A $129,689 noncash loss from remeasuring warrant liabilities affected Q1 results. The filing reports no material change in previously disclosed risk factors, no material litigation accrual, and no off-balance-sheet arrangements.

Important facts for investors to verify

• Confirm the issuer: the supplied filing is Trovagene, Inc., despite the request metadata naming Cardiff Oncology, Inc.
• Track cash use, financing availability, and whether the stated July 2018 cash runway was extended by subsequent events or fundraising.
• Review clinical-trial enrollment, safety, efficacy, and timing for PCM-075, alongside the company’s ability to fund those programs.
• Check subsequent NASDAQ bid-price compliance and the impact of warrant exercises or other equity issuance on dilution.
• Assess recurring operating costs and royalty variability, including the effects of ASC 606 on reported revenue comparisons.